Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Cancer Gene Therapy Market: By Therapy Type, By End-User, and By Region Forecast 2019-2030
Cancer Gene Therapy Market size was valued at US$ 2,688.3 million in 2023 and is anticipated to grow at a CAGR of 24.3% from 2024-2030. Cancer gene therapy, also known as gene-based cancer therapy or gene transfer therapy, is an innovative approach to treating cancer by modifying or manipulating a patient's own genes to target and combat cancer cells. This therapeutic strategy aims to correct genetic mutations, enhance the body's natural immune response, or introduce therapeutic genes into cancerous cells to inhibit their growth and proliferation. The rising incidence of cancer plays a pivotal role in driving the revenues of the market.
According to the American Cancer Society, there were an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States in 2022. As the global burden of various types of cancers continues to increase, there is a growing demand for innovative and effective treatment options beyond traditional methods. Cancer gene therapy, with its potential to target specific genetic mutations and mechanisms driving cancer growth, offers a promising avenue for addressing this growing healthcare challenge. Advancements in genetic research play a pivotal role in propelling the market forward. As our understanding of the genetic underpinnings of cancer deepens, researchers are uncovering specific genetic mutations and alterations that drive the initiation and progression of various cancer types. This intricate knowledge forms the foundation for the development of gene therapies that can precisely target and manipulate cancer-related genes. Advancements in techniques like next-generation sequencing and genome editing technologies enable scientists to identify and modify these genetic abnormalities with greater precision and efficiency.
However, less awareness, and high cost involved in treatment, lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy. Meanwhile, increases in funding from various government and non-government organizations, ethical acceptance of gene therapy for the treatment of diseases, and the growing popularity of DNA vaccines create significant opportunities for the growth of the market. Key market players are developing novel gene therapy approaches that can treat different types of cancer.
Study Period
2024-2030Base Year
2023CAGR
24.3%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as the increase in the prevalence of cancer, rising government initiatives, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, Lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 2,688.3 million |
Market CAGR |
24.3% |
By Therapy Type |
|
By End User |
|
By Region |
|
Download Free Sample Report
The global cancer gene therapy market size was valued at US$ 2,688.3 million in 2023 and is projected to grow at a CAGR of 24.3% from 2024 to 2030.
The advances in gene therapy for the treatments of rare cancers, continued development of advanced gene editing techniques, particularly CRISPR-Cas9, and integration of immunotherapy stand out as significant trends within the market.
Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBionoGeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals., and others are some of the key market players in the market.
1. Executive Summary |
2. Global Cancer Gene Therapy Market Introduction |
2.1. Global Cancer Gene Therapy Market Taxonomy |
2.2. Global Cancer Gene Therapy Market Definitions |
2.2.1. Therapy Type |
2.2.2. End User |
2.2.3. Region |
3. Global Cancer Gene Therapy Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Current Trends |
3.5. Global Cancer Gene Therapy Market Dynamic Factors - Impact Analysis |
3.6. Mergers, Acquisitions, and Collaborations |
4. Global Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Cancer Gene Therapy Market, By Therapy Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1. Gene Induced Immunotherapy |
5.1.1. Delivery of Cytokines Gene |
5.1.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.1.3. Market Opportunity Analysis |
5.1.2. Delivery of Tumor Antigen Gene |
5.1.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.2.3. Market Opportunity Analysis |
5.2. Oncolytic Virotherapy |
5.2.1. Adenovirus |
5.2.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.1.3. Market Opportunity Analysis |
5.2.2. Lentivirus |
5.2.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.2.3. Market Opportunity Analysis |
5.2.3. Retro virus |
5.2.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3.3. Market Opportunity Analysis |
5.2.4. Adeno Associated Virus |
5.2.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.4.3. Market Opportunity Analysis |
5.2.5. Herpes Simplex Virus |
5.2.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.5.3. Market Opportunity Analysis |
5.2.6. Alpha Virus |
5.2.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.6.3. Market Opportunity Analysis |
5.2.7. Vaccinia Virus |
5.2.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.7.3. Market Opportunity Analysis |
5.2.8. Simian Virus |
5.2.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.8.3. Market Opportunity Analysis |
5.2.9. Others |
5.2.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.9.3. Market Opportunity Analysis |
5.3. Gene Transfer |
5.3.1. Naked/Plasmid Vectors |
5.3.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.1.3. Market Opportunity Analysis |
5.3.2. Electroporation |
5.3.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.2.3. Market Opportunity Analysis |
5.3.3. Sonoporation |
5.3.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3.3. Market Opportunity Analysis |
5.3.4. Magnetofection |
5.3.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.4.3. Market Opportunity Analysis |
5.3.5. Gene gun |
5.3.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.5.3. Market Opportunity Analysis |
6. Global Cancer Gene Therapy Market, By End User, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1. Hospitals and Clinics |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Biopharma and Biotechnology Companies |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Academic and Research Institutes |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Cancer Gene Therapy Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1. North America |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Latin America |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. MEA |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Global Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Region, 2024 - 2030 |
8. North America Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
8.1.1. Gene Induced Immunotherapy |
8.1.1.1. Delivery of Cytokines Gene |
8.1.1.2. Delivery of Tumor Antigen Gene |
8.1.2. Oncolytic Virotherapy |
8.1.2.1. Adenovirus |
8.1.2.2. Lentivirus |
8.1.2.3. Retro virus |
8.1.2.4. Adeno Associated Virus |
8.1.2.5. Herpes Simplex Virus |
8.1.2.6. Alpha Virus |
8.1.2.7. Vaccinia Virus |
8.1.2.8. Simian Virus |
8.1.2.9. Others |
8.1.3. Gene Transfer |
8.1.3.1. Naked/Plasmid Vectors |
8.1.3.2. Electroporation |
8.1.3.3. Sonoporation |
8.1.3.4. Magnetofection |
8.1.3.5. Gene gun |
8.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
8.2.1. Hospitals and Clinics |
8.2.2. Biopharma and Biotechnology Companies |
8.2.3. Academic and Research Institutes |
8.2.4. Others |
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
8.3.1. United States |
8.3.2. Canada |
8.4. North America Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
8.5. North America Cancer Gene Therapy Market Dynamics – Trends |
9. Europe Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Gene Induced Immunotherapy |
9.1.1.1. Delivery of Cytokines Gene |
9.1.1.2. Delivery of Tumor Antigen Gene |
9.1.2. Oncolytic Virotherapy |
9.1.2.1. Adenovirus |
9.1.2.2. Lentivirus |
9.1.2.3. Retro virus |
9.1.2.4. Adeno Associated Virus |
9.1.2.5. Herpes Simplex Virus |
9.1.2.6. Alpha Virus |
9.1.2.7. Vaccinia Virus |
9.1.2.8. Simian Virus |
9.1.2.9. Others |
9.1.3. Gene Transfer |
9.1.3.1. Naked/Plasmid Vectors |
9.1.3.2. Electroporation |
9.1.3.3. Sonoporation |
9.1.3.4. Magnetofection |
9.1.3.5. Gene gun |
9.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Hospitals and Clinics |
9.2.2. Biopharma and Biotechnology Companies |
9.2.3. Academic and Research Institutes |
9.2.4. Others |
9.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.3.1. UK |
9.3.2. Germany |
9.3.3. France |
9.3.4. Italy |
9.3.5. Spain |
9.3.6. Rest of Europe |
9.4. Europe Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
9.5. Europe Cancer Gene Therapy Market Dynamics – Trends |
10. Asia Pacific Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
10.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Gene Induced Immunotherapy |
10.1.1.1. Delivery of Cytokines Gene |
10.1.1.2. Delivery of Tumor Antigen Gene |
10.1.2. Oncolytic Virotherapy |
10.1.2.1. Adenovirus |
10.1.2.2. Lentivirus |
10.1.2.3. Retro virus |
10.1.2.4. Adeno Associated Virus |
10.1.2.5. Herpes Simplex Virus |
10.1.2.6. Alpha Virus |
10.1.2.7. Vaccinia Virus |
10.1.2.8. Simian Virus |
10.1.2.9. Others |
10.1.3. Gene Transfer |
10.1.3.1. Naked/Plasmid Vectors |
10.1.3.2. Electroporation |
10.1.3.3. Sonoporation |
10.1.3.4. Magnetofection |
10.1.3.5. Gene gun |
10.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Hospitals and Clinics |
10.2.2. Biopharma and Biotechnology Companies |
10.2.3. Academic and Research Institutes |
10.2.4. Others |
10.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. China |
10.3.2. India |
10.3.3. ANZ |
10.3.4. Japan |
10.3.5. Rest of APAC |
10.4. Asia Pacific Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
10.5. Asia Pacific Cancer Gene Therapy Market Dynamics – Trends |
11. Latin America Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
11.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Gene Induced Immunotherapy |
11.1.1.1. Delivery of Cytokines Gene |
11.1.1.2. Delivery of Tumor Antigen Gene |
11.1.2. Oncolytic Virotherapy |
11.1.2.1. Adenovirus |
11.1.2.2. Lentivirus |
11.1.2.3. Retro virus |
11.1.2.4. Adeno Associated Virus |
11.1.2.5. Herpes Simplex Virus |
11.1.2.6. Alpha Virus |
11.1.2.7. Vaccinia Virus |
11.1.2.8. Simian Virus |
11.1.2.9. Others |
11.1.3. Gene Transfer |
11.1.3.1. Naked/Plasmid Vectors |
11.1.3.2. Electroporation |
11.1.3.3. Sonoporation |
11.1.3.4. Magnetofection |
11.1.3.5. Gene gun |
11.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Hospitals and Clinics |
11.2.2. Biopharma and Biotechnology Companies |
11.2.3. Academic and Research Institutes |
11.2.4. Others |
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Brazil |
11.3.2. Mexico |
11.3.3. Argentina |
11.3.4. Rest of LA |
11.4. Latin America Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
11.5. Latin America Cancer Gene Therapy Market Dynamics – Trends |
12. MEA Cancer Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
12.1. Therapy Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Gene Induced Immunotherapy |
12.1.1.1. Delivery of Cytokines Gene |
12.1.1.2. Delivery of Tumor Antigen Gene |
12.1.2. Oncolytic Virotherapy |
12.1.2.1. Adenovirus |
12.1.2.2. Lentivirus |
12.1.2.3. Retro virus |
12.1.2.4. Adeno Associated Virus |
12.1.2.5. Herpes Simplex Virus |
12.1.2.6. Alpha Virus |
12.1.2.7. Vaccinia Virus |
12.1.2.8. Simian Virus |
12.1.2.9. Others |
12.1.3. Gene Transfer |
12.1.3.1. Naked/Plasmid Vectors |
12.1.3.2. Electroporation |
12.1.3.3. Sonoporation |
12.1.3.4. Magnetofection |
12.1.3.5. Gene gun |
12.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Hospitals and Clinics |
12.2.2. Biopharma and Biotechnology Companies |
12.2.3. Academic and Research Institutes |
12.2.4. Others |
12.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. GCC Countries |
12.3.2. South Africa |
12.3.3. Rest of MEA |
12.4. MEA Cancer Gene Therapy Market - Opportunity Analysis Index, By Therapy Type, End User, and Country, 2016-2027 |
12.5. MEA Cancer Gene Therapy Market Dynamics – Trends |
13. Competition Landscape |
13.1. Strategic Dashboard of Top Market Players |
13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
13.2.1. Urigen Pharmaceuticals Inc. |
13.2.2. GenVec.Inc |
13.2.3. Oxford BioMedica |
13.2.4. Vical |
13.2.5. ANI Pharmaceuticals, Inc. |
13.2.6. Genzyme Corporation |
13.2.7. Novartis AG |
13.2.8. Cell Medica |
13.2.9. Cell Genesys Inc. |
13.2.10. Adaptimmune Therapeutics plc |
13.2.11. Genelux Corporation |
14. Research Methodology |
15. Key Assumptions and Acronyms |
Key Market Players